KRAS and neoplasm: Although some studies showed that the tumor location and KRAS status could affect the effectiveness of patients treated with cetuximab [12, 13], the association between KRAS mutation and patients’ survival remained controversial, as some reports have failed to show any prognostic value of KRAS [14–17].